A Study of the Natural Progression of Interstitial Lung Disease (ILD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT00470327
Recruitment Status : Recruiting
First Posted : May 7, 2007
Last Update Posted : September 11, 2017
Idiopathic Pulmonary Fibrosis Clinical Research Network
Information provided by (Responsible Party):
University of Chicago

Brief Summary:

The purpose of this study is to obtain information on all patients being cared for by the ILD program in an effort to better understand the natural course of these diseases. Hopefully getting this information will lead to a better understanding of how these diseases behave with time. This in turn, will let physicians' better treat patients in the future.

Another goal of the study is to be able to see if in the future a patients' genetics can be linked to the type of disease they have and the way it behaves. We do not yet know what that may be. Our goal is to study this in aggregate rather than in any individual patients. Which genes to study are also unclear. But the only hope of having a clearly defined group to match the genetics to in the future requires that we obtain samples now in conjunction with collecting the data on the disease progression.

Condition or disease
Interstitial Lung Diseases Idiopathic Pulmonary Fibrosis Sarcoidosis

Study Type : Observational
Estimated Enrollment : 4000 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Study of the Natural Progression of Interstitial Lung Disease (ILD)
Study Start Date : September 2005
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2025

Primary Outcome Measures :
  1. Natural history of course of disease in patients with Interstitial lung disease (ILD) [ Time Frame: Yearly ]
    We assess mortality roughly yearly but duration is unlimited

Biospecimen Retention:   Samples With DNA

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Subjects cared for in the ILD (Interstitial Lung Disease)clinic

Inclusion Criteria:

  • Interstitial lung disease

Exclusion Criteria:

  • Does not have Interstitial lung disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00470327

Contact: Spring Maleckar 773-834-4053

United States, Illinois
University of Chicago Recruiting
Chicago, Illinois, United States, 60637
Principal Investigator: Imre Noth, MD         
Sponsors and Collaborators
University of Chicago
Idiopathic Pulmonary Fibrosis Clinical Research Network
Principal Investigator: Imre Noth University of Chicago

Responsible Party: University of Chicago Identifier: NCT00470327     History of Changes
Other Study ID Numbers: 14163A
First Posted: May 7, 2007    Key Record Dates
Last Update Posted: September 11, 2017
Last Verified: September 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: We will share coded data with no PHI

Keywords provided by University of Chicago:
Interstitial lung diseases
idiopathic pulmonary fibrosis
mRNA and cytokine expression

Additional relevant MeSH terms:
Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Lung Diseases
Idiopathic Interstitial Pneumonias
Lung Diseases, Interstitial
Pathologic Processes
Respiratory Tract Diseases
Lymphoproliferative Disorders
Lymphatic Diseases